InnoCan Pharma Corporation (INNPF)
InnoCan Pharma Statistics
Total Valuation
InnoCan Pharma has a market cap or net worth of 46.79 million. The enterprise value is 43.81 million.
| Market Cap | 46.79M |
| Enterprise Value | 43.81M |
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 292.42M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +8.94% |
| Shares Change (QoQ) | +1.15% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 231.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.54 |
| PB Ratio | 6.79 |
| P/TBV Ratio | 10.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 85.70, with an EV/FCF ratio of -90.89.
| EV / Earnings | -67.50 |
| EV / Sales | 1.38 |
| EV / EBITDA | 85.70 |
| EV / EBIT | 92.31 |
| EV / FCF | -90.89 |
Financial Position
The company has a current ratio of 4.08, with a Debt / Equity ratio of 0.19.
| Current Ratio | 4.08 |
| Quick Ratio | 2.84 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | 2.68 |
| Debt / FCF | -2.72 |
| Interest Coverage | 90.80 |
Financial Efficiency
Return on equity (ROE) is 16.61% and return on invested capital (ROIC) is 4.40%.
| Return on Equity (ROE) | 16.61% |
| Return on Assets (ROA) | 2.86% |
| Return on Invested Capital (ROIC) | 4.40% |
| Return on Capital Employed (ROCE) | 5.54% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 3.07 |
| Inventory Turnover | 1.14 |
Taxes
In the past 12 months, InnoCan Pharma has paid 1.21 million in taxes.
| Income Tax | 1.21M |
| Effective Tax Rate | 55.66% |
Stock Price Statistics
The stock price has decreased by -59.90% in the last 52 weeks. The beta is -0.29, so InnoCan Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.29 |
| 52-Week Price Change | -59.90% |
| 50-Day Moving Average | 0.13 |
| 200-Day Moving Average | 0.13 |
| Relative Strength Index (RSI) | 0.59 |
| Average Volume (20 Days) | 2,775 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoCan Pharma had revenue of 30.47 million and -649,000 in losses. Loss per share was -0.00.
| Revenue | 30.47M |
| Gross Profit | 27.30M |
| Operating Income | 454,000 |
| Pretax Income | 2.17M |
| Net Income | -649,000 |
| EBITDA | 489,000 |
| EBIT | 454,000 |
| Loss Per Share | -0.00 |
Balance Sheet
The company has 6.37 million in cash and 1.31 million in debt, giving a net cash position of 5.06 million.
| Cash & Cash Equivalents | 6.37M |
| Total Debt | 1.31M |
| Net Cash | 5.06M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 6.89M |
| Book Value Per Share | 0.02 |
| Working Capital | 8.08M |
Cash Flow
In the last 12 months, operating cash flow was -464,000 and capital expenditures -18,000, giving a free cash flow of -482,000.
| Operating Cash Flow | -464,000 |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -482,000 |
| FCF Per Share | n/a |
Margins
Gross margin is 89.61%, with operating and profit margins of 1.49% and -2.13%.
| Gross Margin | 89.61% |
| Operating Margin | 1.49% |
| Pretax Margin | 7.13% |
| Profit Margin | -2.13% |
| EBITDA Margin | 1.61% |
| EBIT Margin | 1.49% |
| FCF Margin | n/a |
Dividends & Yields
InnoCan Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.94% |
| Shareholder Yield | n/a |
| Earnings Yield | -1.39% |
| FCF Yield | -1.03% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoCan Pharma has an Altman Z-Score of 6.59 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.59 |
| Piotroski F-Score | 5 |